Drug drug interactions highlighting P450 Cytochromes. Louis Wu, PA-C Presented at VAPAA Annual Meeting March 2, 2017
|
|
- Elinor Dickerson
- 5 years ago
- Views:
Transcription
1 Drug drug interactions highlighting P450 Cytochromes Louis Wu, PA-C Presented at VAPAA Annual Meeting March 2, 2017
2 Financial Disclosures and Conflicts I have no financial disclosures nor conflicts concerning this talk.
3 Learning Objectives Develop a basic understanding of pharmacodynamics and pharmcokinetics as it applies to drug interactions Conceptualize the cytochrome P450 enzyme system; enzyme inhibition and enzyme induction Review potential hazards of drug interactions in older populations Be able to access drug interaction resources on the VA CPRS system as well as online such as FDA website and publications such as Medical Letter
4 Why doesn t your patient respond to the medication? Adherence Age of the patient Disease State Drug-drug and food-drug interactions Gender Genetics Others Langman and Dasgupta, in Pharmacogenomics in Clinical Therapeutics, 2012, pp 1-4
5 What is the problem with drug-drug Precipitant drug interactions? Object (or substrate) drug Drug interaction between the two that increases or decreases the concentration of the object drug If significant enough, then the patient develops a drug toxicity or an inadequate therapeutic response from the object drug Hansten, PD.in Levy et al, Metabolic Drug Interactions, 2000, pg 715
6 Mechanism of drug interaction 1. Pharmacodynamic one drug affects the ability of another drug to associate with its therapeutic target or receptor Examples: Methotrexate and Trimethoprim/sulfamethoxazole Epinephrine and non selective beta-blockers Grattagliano, J Fam Prac, 2010 (59) 6:
7 Mechanism of drug interaction 2. Pharmacokinetic: from drug absorption to elimination D - distribution A - absorption M metabolism (P450 Cytochrome system) E - elimination Grattagliano, J Fam Prac, 2010 (59) 6:
8 Really fundamental concepts in drug biotransformation Lipid soluble drugs are poorly excreted in the urine. They tend to store in fat and/or circulate until they are converted (phase I biotransformation) to more water soluble metabolites or metabolites that conjugate (phase II biotransformation) with water soluble substances. Water soluble drugs are more readily excreted in the urine. They may be metabolized, but generally not by the CYP enzyme systems.
9 What is P450 Cytochrome System? A composite of 30 plus isoenzymes referred to as CYP (cytochrome P450) Carries out first phase of biotransformation for a variety of drugs (the substrate drugs) Of significance: CYP 1A2 CYP 2C9 CYP 2C19 CYP 2D6 CYP 2E1 CYP 3A4 Grattagliano, J Fam Prac, 2010 (59) 6:
10 Cytochrome P450 Nomenclature CYP = cytochrome P450 2 = genetic family D = genetic sub-family 6 = specific gene NOTE: This nomenclature is genetically based; it does not imply chemical specificity Grattagliano, J Fam Prac, 2010 (59) 6:
11 ROLE OF CYP ENZYMES IN HEPATIC DRUG METABOLISM RELATIVE HEPATIC CONTENT OF CYP ENZYMES % DRUGS METABOLIZED BY CYP ENZYMES CYP2D6 2% CYP2E1 7% CYP 2C 17% CYP 1A2 12% CYP 3A4-5 26% OTHER 36% CYP 2C9 14% CYP 1A2 14% CYP 2C19 11% CYP 3A4-5 33% CYP2D6 23% CYP2E 5% Slide set, S.P. Markey, NIH, 2006
12 Drug Interactions (Liver) CYP Substrate CYP Inhibitor Substrate concentration Toxicity CYP Substrate CYP Inducer Substrate concentration Efficacy
13 Inhibitors of P-450 Results in decreased metabolism and hepatic clearance of the substrate drug Example: Prolonged warfarin effect Warfarin as the substrate combined with Amiodarone as the inhibitor Lynch and Price, Am Fam Physician Aug 1;76(3):
14 Inducers of P-450 Results in increased metabolism and increased hepatic clearance of the substrate Example: Decreased Oral Contraceptive effect ethinyl estardiol as the substrate combined with Tegretol as the inducer Lynch and Price, Am Fam Physician Aug 1;76(3):
15 Drug Metabolism Active drug Enzyme (inactivated by enzyme) Drug Inactive Metabolite Prodrug (needs enzyme to Enzyme produce active drug) Prodrug Active Metabolite
16 Then there are pro-drugs Pro-Drug Plus an inhibitor Pro-Drug does not break down to active metabolites Plus an inducer Pro-Drug breaks down to active metabolites Pro-drug stays pretty much unmetabolized Active metabolites are excessive
17 P-Glycoprotein Drug Transporters Drug efflux transporter with interactions similar to that of CYP3A4; notable example is digoxin as substrate and carvedilol or quinidine as P-gp inhibitors resulting in prolonged digoxin effect The Medical Letter, 2003; (45): 46-48
18 Case 1. Fluconazole and Warfarin EUROPEAN JOURNALOF EMERGENCYMEDICINE, 2002, 9, A 75-year-old man on chronic anticoagulation with warfarin for atrial fibrillation and transient ischaemic attacks Found to have Candidasis on EGD specimen and Fluconazole given for 4 weeks. Five weeks later presented to the emergency department with complaints of back pain of three days duration radiating to both legs and leg weakness. His INR was found to be 40 MRI of the thoracic spine demonstrated a posterior epidural haematoma extending from T3 to T10 and an emergent laminectomy was performed.
19 CYP2C9 and Warfarin If possible, fluconazole should not be used for patients anticoagulated with warfarin. Otherwise close monitoring is required.
20 dabigatran (Pradaxa) and rivaroxaban (Xarelto) Known as a direct thrombin inhibitor (dabigatran) or direct Factor Xa inhibitor (rivaroxaban) Both are approved to reduce the risk of stroke and blood clots (systemic embolism) in patients with non-valvular atrial fibrillation. XARELTO is also indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery. Drug interactions with p-glycoproteins, CYP34A Prescriber's Letter 2011; 18(12):271220
21 Case 2. Simvastatin and Amiodarone Ann Pharmacother 2006;40: A 72-year-old white man presented with thigh weakness, achiness, and dark urine for 7 days. Coronary artery bypass had been performed earlier and Amiodarone 200 mg/day was started and later simvastatin 80 mg/day was added Labs included creatine kinase (CK) U/L (reference range ), blood urea nitrogen 50 mg/dl, creatinine 2.6 mg/dl, (AST) 912 U/L (30 60), (ALT) 748 U/L (30 60), urine myoglobin μg/l (<50), and serum myoglobin μg/l (<110).
22 Rhabdomyolysis Adapted from: Sinoway L, Li J. J Appl Physiol 2005;99:5 22.
23 CYP3A4 and Statins Simvastatin is metabolized primarily by CYP3A4, and amiodarone is a recognized inhibitor of this enzyme
24 Facts about statins A class of prescription drugs used together with diet and exercise to reduce blood levels of lowdensity lipoprotein (LDL) cholesterol Marketed as single-ingredient products, including Lipitor (atorvastatin), Lescol (fluvastatin), Mevacor (lovastatin), Altoprev (lovastatin extendedrelease), Livalo (pitavastatin), Pravachol (pravastatin), Crestor (rosuvastatin), and Zocor (simvastatin) Also marketed as combination products, including Advicor (lovastatin/niacin extended-release), Simcor (simvastatin/niacin extended-release), and Vytorin (simvastatin/ezetimibe)
25 A word from the FDA Do not use simvastatin with these medications: Itraconazole Ketoconazole Gemfibrozil Cyclosporine Danazol Posaconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Nefazodone
26 A word from the FDA Do not use more than 10mg of simvastatin with these medications: Verapamil, Diltiazem (Note: These drugs are contraindicated with Simcor as Simcor is only available with 20 mg or 40 mg of simvastatin.) Do not use more than 20mg of simvastatin with these medications: Amlodipine, Amiodarone, Ranolazine Avoid large quantities of grapefruit juice (>1 quart daily)
27 Lovastatin Dose Limitations Contraindicated with lovastatin: Itraconazole Ketoconazole Posaconazole Erythromycin Clarithromycin Telithromycin HIV protease inhibitors Boceprevir Telaprevir Nefazodone
28 Lovastatin Dose Limitations Avoid with lovastatin: Cyclosporine Gemfibrozil Do not exceed 20 mg lovastatin daily with: Danazol Diltiazem Verapamil Do not exceed 40 mg lovastatin daily with: Amiodarone Avoid large quantities of grapefruit juice (>1 quart daily)
29 Case 3. Tamoxifen and SSRI Am J Psychiatry 165:10, October 2008 Ms. B is a 45-year-old woman who was diagnosed with major depressive disorder treated with fluoxetine One year ago, she was diagnosed with breast cancer and underwent surgery, followed by chemotherapy, and then radiation therapy. Tamoxifen (a selective estrogen receptor modulator) added to prevent breast cancer recurrence. What potential problems do you forsee?
30 CYP2D6 and Fluoxetine CYP2D6 is necessary for conversion of the prodrug tamoxifen to its primary active metabolite endoxifen. Fluoxetine is a strong CYP2D6 inhibitor, and therefore inhibits the conversion tamoxifen to endoxifen and compromise the efficacy of tamoxifen. Citalopram (Celexa ), sertraline (Zoloft ), and venlafaxine (Effexor ) do not significantly inhibit CYP2D6
31 Case 4. Plavix and PPIs Cardiology in Review Volume 17, Number 4, July/August 2009 A 52-year-old man found to have 80% stenosis in the right coronary artery and a drug-eluting stent placed. On discharge, patient was on metoprolol 25 mg twice daily, lisinopril 5 mg once daily, pravastatin 40 mg once daily, aspirin 325 mg once daily, clopidogrel 75 mg once daily, and pantoprazole 40 mg once daily (for stress ulcer prophylaxis during coronary care unit stay). Should a PPI be continued for gastrointestinal (GI) ulcer prophylaxis? If so, is there a preferred PPI to use in this case?
32 CYP2C19 and Plavix Clopidogrel (Plavix ) is a prodrug. Omeprazole (Prilosec ) is thought to inhibit the CYP2C19 metabolism of clopidogrel to its active metabolite. Concomitant use of omeprazole and clopidogrel to be avoided. Unknown to what extent other PPIs may interact with clopidogrel. However, esomeprazole (Nexium ) also inhibits CYP2C19 and should also be avoided.
33 Do you like controversies? FDA Advisory: Concomitant use of clopidogrel and omeprazole should be avoided may not get full protective anticlotting effect The Medical Letter: Patients at risk for upper GI bleeding who take clopidogrel should also take a PPI, but not Omeprazole Pantoprazole would be reasonable choice The Medical Letter, Nov 29, 2010 (52): 93
34 Do you like controversies? ACCF / ACG / AHA 2010 Expert Consensus: Pharmacokinetic and pharmacodynamic studies suggest that concomitant use of clopidogrel and a PPI reduces the antiplatelet effects of clopidogrel It is not established that changes in these surrogate endpoints translate into clinically meaningful differences J. Am. Coll. Cardiology. 2010; (56):
35 Case 5. Digoxin and Itraconazole Annals of Int Med, 1992; 116 (6): y/o man with chronic atrial fib treated with Digoxin for rate control Found to have elbow swelling with positive fungal culture on aspirate Treated with ketoconazole with no effect and switched to itraconazole Two weeks later, developed nausea and vomiting which resolved after itraconazole was stopped
36 P-Glycoprotein Drug Transporters Drug efflux transporter with interactions similar to that of CYP3A4; notable example is digoxin as substrate and carvedilol or quinidine as P-gp inhibitors resulting in prolonged digoxin effect The Medical Letter, 2003; (45): 46-48
37 Elderly and Polypharmcy By some estimates patients 65 and older average 8 different drugs daily Frequently used: Nonnarcotic analgesic Calcium channel blocker Diuretics Antidepressants ACE inhibitors Rathore et al, Fam Med (1998); 30:
38 Why the elderly are more susceptible to adverse drug reactions Aging state: renal clearance diminished, hepatic drug metabolizing enzyme activity lessened, and drug sensitivity heightened Commonly seen: prolonged opioid, benzodiazepine and CNS depressant effects and bleeding from anticoagulation; paradoxically less responsive to beta adrenergic blockers and agonists Cooney and Pascuzzi, Clin Geriatr Med, 2009 (25):
39 The Beers Criteria (age over 65) Medications or medication classes that generally should be avoided due to ineffectiveness or unnecessarily high risk when safer alternatives are available Medications should not be used due to concurrent medical conditions Fick et al, Arch Int Med 2003; (163):
40 Elderly and Adverse Drug Effects Four medications or medication classes were implicated alone or in combination in 67.0% of emergency hospitalizations Warfarin (33.3%) Insulins (13.9%), Oral antiplatelet agents (13.3%), and Oral hypoglycemic agents (10.7%) High-risk medications were implicated in only 1.2% hospitalizations.
41 Common presentation on admission Acute hemorrhages Hypoglycemia Neurologic symptoms (loss of consciousness, seizures, changes in mental status). Electrolyte or fluid-volume disturbances or nonspecific weakness NEJM, 2011; 365:
42 3 drug interactions in elderly leading to hospitalizations Population-based case control study of Canadian residents over age 66 Hospitalization with glyburide, digoxin, or ACE-I when combined with other drugs vs similar matched controls Glyburide + co-trimoxazole Digoxin + clarithyromycin ACE-I + potassium sparing diuretic Juurlink et al., JAMA (2003), 289:
43 Minimizing Drug Interaction Risks L List each drug s name and dosage I Indication and clearly defined therapeutic goal; discontinue if not S Simple regimen as possible with once or twice a day dosing T Treat multiple symptoms with single drug rather than multiple drugs E Educate patients about adverse events and address all non prescriptions and supplements N Narrow therapeutic window drugs, avoid Werder, J Fam Prac 2005 (4) 5
44 To Reduce Risk of Adverse Drug Interactions Use of alternative noninteracting medications Adjust dose of object drug: when possible based on changes in response rather than prophylactically ( to avoid sub or supra dosing) Adjust dosing times (object drug two hours before or six hours after the binding drug) Monitor for altered response (lab monitoring) Computerized system to avoid adverse drug interactions (still patients may have multiple providers and multiple pharmacies)
45 Alternative Noninteracting Medications Drug Class Interaction Susceptible Alternatives Benzodiazepine CYP3A4 Inhibition Alprazolam, Diazepam, Midazolam, Triazolam Lorazepam, Oxazepam, Temazepan Calcium Channel Blockers CYP3A4 Inhibition Diltiazem, Verapamil Dihydropyridine CCB Coumarin anticoagulants CYP2C9 Inhibition Acenocoumarol, Warfarin Phenprocoumon dabigatran and rivaroxaban HMG-CoA reductase inhibitor CYP3A4 Inhibition Lovastatin Simvastatin Fluvastatin, Pravastatin Hansten, P.D. in Levy et al, Metabolic Drug Interactions, 2000, pg 725
46 Alternative Noninteracting Medications Drug Class Interaction Susceptible Alternatives H2-receptor antagonists Various CYP 450 isoenzymes Inhibition Cimetidine Famotidine, Nizatidine, Ranitidine Macrolide antibiotics CYP3A4 Inhibition Clarithromycin, Erthyromycin Azithromycin, Dirithromycin Quinolone antibiotics CYP1A2 Inhibition Ciprofloxacin, Enoxacin, Grepafloxacin Levofloxacin, Ofloxacin, Lovafloxacin, Sparfloxacin, Trovafloxacin Selective serotonin reuptake inhibitors CYP2D6 Inhibition Fluoxetine, Paroxetine Citalopram, Fluvoxamine, Sertraline
47 Avoiding Drug Interactions for Consumers
48 Reporting Adverse Drug Effects to Food and Drug Administration (FDA) default.htm
49 General References 1. Cozza, K. Drug Interactions. 2003, American Psychiatric Publishing Inc 2. (100 Top Drug Interactions) 3. (P450-mediated interactions) For Simvastatin product information (pay site) 8. (pay site) 9. (pay site and apps)
50 In Summary Health care providers must pay attention to patients taking multiple drugs Significant drug interactions are clinically important if they retard or accentuate the normal effects of drugs Consult tables such as the P450 cytochrome system or your electronic pharmacology software or call your pharmacist if there is a question about interactions Elderly patients require special attention Education of the patient and ongoing education of the clinician to drug interactions is essential to good care
RISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY
RISK FACTORS AND DRUG INTERACTION PREDISPOSING TO STATIN-INDUCED MYOPATHY Assist. Prof. Dr. Verawan Uchaipichat Clinical Pharmacy Department Khon Kaen University Advanced Pharmacotherapy 2012 Updated d
More informationCholesterol. Medicines To Help You
Medicines To Help You Cholesterol Use this guide to help you talk to your doctor, pharmacist, or nurse about your cholesterol medicines. The guide lists all of the FDA-approved products now available to
More informationWho remembers Terfenadine? Once daily non-sedating anti-histamine. Drug Interactions: What is the CYP 450 system? What does the CYP 450 system do?
Drug Interactions: Things that go BOOM! Who remembers Terfenadine? Once daily non-sedating anti-histamine Amelie Hollier, DNP, FNP-BC, FAANP Advanced Practice Education Associates A strange thing happened
More informationDrug Interactions for the Emergency Physician. Lisa Thurgur
Drug Interactions for the Emergency Physician Lisa Thurgur Objectives Why we should care about drug-drug interactions Cases How can we avoid these interactions Short list of culprit drugs Drug-Drug Interaction
More informationMedications for Treating Stroke
Medications for Treating Stroke Subject Expert Sonny Kupniewski, PharmD, BCPS Swedish Medical Center Englewood, CO 2 Objectives Medications used to prevent stroke Prevention of strokes in patients with
More informationTo understand the formulary process from the hospital perspective
Formulary Process Michael A. Militello, Pharm.D. Cleveland Clinic Cleveland Clinic 2011 Goal and Objectives To understand the formulary process from the hospital perspective p To list the various panels
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationA mong the 20 leading prescription
Safety and Statins: Pharmacologic and Clinical Perspectives Michael B. Bottorff, PharmD A mong the 20 leading prescription drugs in the United States, 3 agents atorvastatin (Lipitor), simvastatin (Zocor),
More informationCytochrome P450 Drug Interaction Table Flockhart Table
Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A
More informationVI.2 Elements for a public summary. VI.2.1 Overview of disease epidemiology
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology This medicine is used to lower levels of total cholesterol, LDL cholesterol ( bad cholesterol), and fatty substances called triglycerides
More informationClinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date:
Clinical Policy: Pitavastatin (Livalo), Ezetimibe/Simvastatin (Vytorin 10/10 mg) Reference Number: CP.CPA.62 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationComprehensive Drug Information for Smith, John
PATIENT INFORMATION Name: Smith, John DOB: April 22, 1973 Age: 42 Sex: Male SAMPLE Date Collected: March 21, 2016 Date Received: March 21, 2016 Case ID: CARDI16-000001 Source: Buccal Swabs Comprehensive
More informationNibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr SIMVASTATIN 5 Pr SIMVASTATIN 10 Pr SIMVASTATIN 20 Pr SIMVASTATIN 40 Pr SIMVASTATIN 80 Simvastatin Tablets, USP This leaflet is part III of a three-part Product Monograph
More informationSelf Assessment Question 1
Drug Interactions Bruce G. Pollock, M.D., Ph.D. Professor of Psychiatry, Pharmacology and Nursing Chief, Academic Division of Geriatrics and Neuropsychiatry University of Pittsburgh Medical Center 1 Self
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationDOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
More informationElements for a public summary
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Cardiovascular disease (CVD) is responsible for one-third of global deaths and is a leading and increasing contributor to the
More informationNanik Hatsakorzian Pharm.D/MPH
Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome
More informationAntihyperlipidemic drugs
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual
More informationCardiovascular Drugs and Therapies HMG CoA a REDUCTASE INHIBITORS (available in Canada)
Trade Name Dosage Forms 10 mg, 20 mg, 40 mg, 80 mg tablets Dosing Range 10-80 mg once daily 2 Dosing Based on Desired LDL Reduction 1,2,3 HMG CoA a REDUCTASE INHIBITORS (available in Canada) LIPITOR, generics
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationAre the days of Warfarin numbered?
2 nd SAVTE Symposium Are the days of Warfarin numbered? YES Dr. Mohamed A. Abdelaal, MD, FRCPath, FRCPI Consultant Haematologist King Abdulaziz Medical City - Jeddah, Saudi Arabia 1 3 May 2012, Casablanca,
More informationFrequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System
ORIGINAL RESEARCH Frequency of Simvastatin Prescriptions With Potentially Interacting Medications in a Veterans Affairs Health Care System JERILYN B. PETROPOULOS, BSPharm, PharmD, BCPS, and CRISTINA E.
More informationDrug Use Criteria: Direct Oral Anticoagulants
Texas Vendor Drug Program Drug Use Criteria: Oral Anticoagulants Publication History 1. Developed March 2017. 2. Revised February 2018. Notes: Information on indications for use or diagnosis is assumed
More informationDrug Interactions Year 2 Clinical Pharmacology
1 Drug Interactions Year 2 Clinical Pharmacology Prof Mark McKeage Department of Pharmacology & Clinical Pharmacology 2 Objectives Explain the potential for interacting drugs to cause beneficial and harmful
More informationCytochrome P450 interactions
Cytochrome P450 interactions Learning objectives After completing this activity, pharmacists should be able to: Explain the mechanism of action of clopidogrel-ppi interaction Assess the risks and benefits
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Ezetimibe/simvastatin is used to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD). CHD occurs
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. A. Prescriptions That Require Prior Authorization
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Anticoagulants A. Prescriptions That Require Prior Authorization Prescriptions for Anticoagulants
More information1.* Dosage. A. Adults
3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors [Developed, November 1994; Revised, October 1996; September 1997; September 1998; October 1999; November 1999; August 2000; September
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationFORTH VALLEY. LIPID LOWERING GUIDELINE v5 2016
FORTH VALLEY LIPID LOWERING GUIDELINE v5 2016 This guideline applies to people over 16 years of age. This guideline is not intended to serve as a standard of medical care or be applicable in every situation.
More informationsrmp Atorvastatin Medical Valley
srmp Atorvastatin Medical Valley VI.2 VI.2.1 Elements for a public summary Overview of disease epidemiology This product is indicated for the lowering of cholesterol blood levels and the prevention of
More informationAFPC Conference InterMed-Rx : Harmony and optimal therapy in the use of medication. June
AFPC Conference 2009 InterMed-Rx : Harmony and optimal therapy in the use of medication June 5 2009 Jacques Turgeon, B.Pharm., Ph.D. Full professor, Faculty of pharmacy Research Director, CHUM Université
More informationDrug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Gout i Gout has a worldwide distribution. In the United Kingdom from 2000 to 2007, the estimated occurrence of gout is 5.9% in
More informationBMS Project ID: 432US /16
The Bristol-Myers Squibb/Pfizer Medical Alliance would like to inform you that the following sections of the prescribing information for ELIQUIS (apixaban) have been updated and the underlined text denotes
More informationDabigatran 101: Community Pharmacists. Peter Thomson Clinical Resource Pharmacist, Medicine Program Winnipeg Regional Health Authority
Dabigatran 101: Community Pharmacists. Peter Thomson Clinical Resource Pharmacist, Medicine Program Winnipeg Regional Health Authority Objectives At the end of this session, you should be able to: Describe
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationRHABDOMYOLYSIS AFTER ADDITION OF DIGITOXIN TO CHRONIC SIMVASTATIN AND AMIODARONE THERAPY
RHABDOMYOLYSIS AFTER ADDITION OF DIGITOXIN TO CHRONIC SIMVASTATIN AND AMIODARONE THERAPY H Nägele (1)*, S.Behrens (1), S. Hashagen (1), M Azizi (2) 1) St. Adolfstift, Medical Clinic, Reinbek, Germany (Director:
More informationCOMPUTER ALERT FATIGUE DON T IGNORE THESE IMPORTANT DRUG-DRUG INTERACTIONS. Dan Malone, RPh, PhD Professor University of Arizona
COMPUTER ALERT FATIGUE DON T IGNORE THESE IMPORTANT DRUG-DRUG INTERACTIONS Dan Malone, RPh, PhD Professor University of Arizona Disclosures I, Daniel Malone, have no financial relationships to disclose
More informationOutpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015
Outpatient Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin (LMWH) Clinical Practice Guideline August 2015 General Principles: There is compelling data in the medical literature to support
More informationDrug Interactions Year 2 Clinical Pharmacology
1 Drug Interactions Year 2 Clinical Pharmacology Dr Susannah O Sullivan Department of Pharmacology University of Auckland 2 Objectives Explain the potential for interacting drugs to cause beneficial and
More informationQUEST FOR THE IDEAL ANTICOAGULANT: A PATIENT-CENTERED APPROACH TO TREATMENT
QUEST FOR THE IDEAL ANTICOAGULANT: A PATIENT-CENTERED APPROACH TO TREATMENT SATURDAY/11:30AM-12:30PM ACPE UAN: 0107-9999-17-237-L01-T 0.1 CEU/1.0 hr Activity Type: Knowledge-Based Learning Objectives for
More informationMedicines save lives
Optimizing Aging Collaborative Disclosures Too much of a good thing: No financial interests to disclose John Newman, MD, PhD Assistant Professor Division of Geriatrics, UCSF Kirby Lee, PharmD, MAS Associate
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationPharmacologic Considerations of HCV Treatment. Autumn Zuckerman, PharmD, BCPS, AAHIVP
Pharmacologic Considerations of HCV Treatment Autumn Zuckerman, PharmD, BCPS, AAHIVP Objectives Review pharmacokinetic properties of currently utilized Hepatitis C medications Review drug interactions
More informationSimvastatin 40 mg equivalent
Simvastatin 40 mg equivalent medications equivalent to Simvastatin is available on the Drugs.com website. Simvastatin (Zocor ): 10 mg : Equivalent Dosages - 3: Atorvastatin (Lipitor. 40 mg : Equivalent
More informationDynamic DNA Laboratories, LLC - DO NOT DISTRIBUTE
Cardiovascular Pharmacogenetic Report Created for: Patty Pain Patient: Patty Pain DOB: 1/1/1970 Accession #: 988889 SSN: Collection Date: Received Date: Ordering Physician: Report Generated: 1/28/2016
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationStatin intolerance. Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France
Statin intolerance Pr Franck Boccara, MD, PhD Cardiologie, INSERM UMRS938 CHU St Antoine, UPMC, Paris, France Disclosure Statement of Financial Interest I currently have, or have had over the last two
More informationCARDIAC REHABILITATION PROGRAMME:- MEDICATION
CARDIAC REHABILITATION PROGRAMME:- MEDICATION AIM OF THIS SESSION Understand the reasons for taking your medications, Discuss the common side effects associated with these medications - knowing when to
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationConflicts of interest. What's the Skinny on the Lipid Guidelines? Key Differences. Are you applying the new ACC/AHA Lipid guidelines in your practice?
Conflicts of interest What's the Skinny on the Lipid Guidelines? The presenter has no relevant conflicts of interest to disclose. Kathleen Vest, PharmD, CDE, BCACP At the end of this presentation, pharmacist
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationPotential Drug Dosing Variability in Women. Jim Beaulieu, PharmD Senior Clinical Pharmacist Specialist Rhode Island Hospital and The Miriam Hospital
Potential Drug Dosing Variability in Women Jim Beaulieu, PharmD Senior Clinical Pharmacist Specialist Rhode Island Hospital and The Miriam Hospital 2 Objectives Understand the pharmacokinetic variability
More informationClinical Policy: Lomitapide (Juxtapid) Reference Number: ERX.SPA.170 Effective Date:
Clinical Policy: (Juxtapid) Reference Number: ERX.SPA.170 Effective Date: 01.11.17 Last Review Date: 08.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationPreventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE
Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE What Is Atrial Fibrillation? Atrial fibrillation also called AFib or AF is the most common abnormal heart rhythm, affecting an
More information12/19/16. Disclosures
@atriumrx Don t Miss a Beat! Practical Tips on Managing Drug-Induced QTc Prolongation Sandeep Devabhakthuni, PharmD, BCPS- AQ Cardiology Assistant Professor University of Maryland School of Pharmacy Disclosures
More informationAtrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted.
Patient Name: Diagnosis: Allergies with reaction type: Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Telemetry Medical Telemetry:
More informationXarelto (rivaroxaban) Prescriber Guide
Xarelto (rivaroxaban) Prescriber Guide October 2018 PP-XAR-IE-0031 Contents Patient Alert Card 4 Dosing Recommendations 4 Stroke prevention in adult patients with non-valvular atrial fibrillation 4 Patients
More informationTim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio
Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Medical University Objectives 1. 2. 3. 4. Review and discuss
More informationAtrial Fibrillation Topics for Today. Clinical Controversies Management of Atrial Fibrillation. Atrial Fibrillation in the ER Topics for Today
Clinical Controversies Management of Atrial Fibrillation Yerem Yeghiazarians, M.D. Associate Professor of Medicine Leone-Perkins Family Endowed Chair in Cardiology Atrial Fibrillation Topics for Today
More informationUpdates in Management of Venous Thromboembolic Disease
Updates in Management of Venous Thromboembolic Disease November 7 th 2018 UHN Emergency Conference Susan Jenkins RN(EC) NP-Adult Thrombosis and Hemostasis Program University Health Network Disclosures
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationNHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing
NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: 01233 618158
More informationNEW ZEALAND DATASHEET
1. PRODUCT NAME PRADAXA 75 mg hard capsules PRADAXA 110 mg hard capsules PRADAXA 150 mg hard capsules NEW ZEALAND DATASHEET 2. QUALITATIVE AND QUANTITATIVE COMPOSITION PRADAXA 75 mg hard capsules Each
More informationDangerous Liaisons: Drug-drug, drug-nutrient interactions. Disclosure
Dangerous Liaisons: Drug-drug, drug-nutrient interactions Monica Tombasco, MS, MSNA, FNP-BC, CRNA Senior Lecturer, Fitzgerald Health Education Associates, LLC North Andover, MA Emergency Medicine Nurse
More information:{ic0fp'16. Geriatric Medicine: Optimal Heart Health Amid Changing Guidelines. (and the Evidence for When to Stray) Kevin Overbeck, DO
:{ic0fp'16 ACOFP 53 rd Annual Convention & Scientific Seminars Geriatric Medicine: Optimal Heart Health Amid Changing Guidelines (and the Evidence for When to Stray) Kevin Overbeck, DO Optimal Heart Health
More informationIt is the policy of health plans affiliated with PA Health & Wellness that Vytorin is medically necessary when the following criteria are met:
Clinical Policy: Ezetimibe and Simvastatin (Vytorin) Reference Number: PA.CP.PMN.77 Effective Date: 02.01.17 Last Review Date: 07.18 Revision Log Description Ezetimibe/simvastatin (Vytorin ) contains ezetimibe,
More informationCOMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK
COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics
More informationWMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT
WMC PHARMACY ANTICOAGULATION PROTOCOL Current Revision: July 2017 GENERAL ORDER PROCESSING AND MANAGEMENT - Entering orders for anticoagulation in Cerner Providers will enter individual orders (oneoffs)
More informationObjectives. Safe Prescribing and Drug-Drug Interactions for the Nurse Practitioner
Safe Prescribing and Drug-Drug Interactions for the Nurse Practitioner Wendy L. Wright, MS, ANP-BC, FNP-BC, FAANP, FAAN, FNAP Family Nurse Practitioner Owner - Wright & Associates Family Healthcare Amherst,
More informationDrug Use Criteria: 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors (Statins)
Texas Vendor Program Use Criteria: 3-Hydroxy-3-Methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors (Statins) Publication History Developed November 1994. Revised March 2018; March 2017; December 2014;
More informationObjectives. Having completed the learning activities, the participant will be able to: Dyslipidemia: The latest treatment recommendations
Objectives Dyslipidemia: The latest treatment recommendations Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC President, Fitzgerald Health Education Associates, Inc. North Andover, MA
More informationOverview of anticoagulants David Perry
Chapter 2 Overview of anticoagulants David Perry Historically anticoagulation involved the use of heparin and its derivatives or warfarin. However, the past few years have seen the introduction of a number
More informationQuality ID #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care
Quality ID #438: Statin Therapy for the Prevention and Treatment of Cardiovascular Disease National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE
More informationImportance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data
pubs.acs.org/crt Importance of Multi-P450 Inhibition in Drug Drug Interactions: Evaluation of Incidence, Inhibition Magnitude, and Prediction from in Vitro Data Nina Isoherranen,* Justin D. Lutz, Sophie
More informationThe Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now. Bradley A. Hardin, MD Richard F.
The Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now Bradley A. Hardin, MD Richard F. Otten, MD, FACC Outline Atrial Fibrillation Overview Overview of New Oral Anticoagulants
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Lipid disorders: Disorders of lipid metabolism are manifest by elevation of the plasma concentrations of the various lipid and lipoprotein fractions (total and LDL cholesterol,
More informationSouthern Trust Anticoagulant Team
CLINICAL GUIDELINES ID TAG Title: Author: Speciality / Division: Directorate: Anticoagulation- Primary Care Guidance for reviewing patients on DOACs Southern Trust Anticoagulant Team Haematology Acute
More informationDrug Drug Interactions in Cardiovascular Catheterizations and Interventions
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 12, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.10.005
More informationThere is some evidence to suggest that the half-life of felbamate may be prolonged by gabapentin.
amciclovir amciclovir + Probenecid Probenecid is predicted to increase the exposure to penciclovir, the active metabolite of famciclovir, possibly resulting in increased adverse effects. Evidence is limited
More informationThe Case of Libby Zion and Dangerous Drug Interactions
The Case of Libby Zion and Dangerous Drug Interactions J.R.White, PA, PharmD I. MAOI and Meperidine Libby Zion 18 yo female Rx c phenelzine (Nardil) Meperidine given for shaking chills Outcome Death Libby
More informationDirect Oral Anticoagulants
Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish
More informationIf yes, continue to #2. If no, do not approve. DENIAL TEXT: See the initial denial text at the end of the guideline.
Generic Brand HICL GCN Exception/Other LOMITAPIDE JUXTAPID 39883 This drug requires a written request for prior authorization. All requests for Juxtapid (lomitapide) require review by a pharmacist prior
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationRhabdomyolysis from the Combination of a Statin and Gemfibrozil: An Uncommon But Serious Adverse Reaction
Rhabdomyolysis from the Combination of a Statin and Gemfibrozil: An Uncommon But Serious Adverse Reaction Amy Haavisto Kind, MD; Laura J. Zakowski, MD; Patrick E. McBride, MD ABSTRACT We report a patient
More informationNovel Anticoagulants PHYSICIANS UPDATE 2014
Novel Anticoagulants PHYSICIANS UPDATE 2014 Farouk Mookadam MD FRCPC FACC MSc Professor College of Medicine Mayo Consultant Cardiovascular Diseases Medical Director Anticoagulation Clinic Assoc Programme
More information10/22/2012 UPDATE IN CARDIOLOGY WHAT S NEW EXCITING AND DIFFERENT. I have no conflicts of interest to disclose AF PREVALENCE INCREASES WITH AGE
CONFLICT OF INTEREST DISCLOSURES UPDATE IN CARDIOLOGY WHAT S NEW EXCITING AND DIFFERENT I have no conflicts of interest to disclose Barbara S. Wiggins, Pharm.D., BCPS, CLS, FNLA, FCCP, FAHA, AACC Clinical
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationJuly 2011 Medical Update Information
July 2011 Medical Update Information Simvastatin (Zocor) new FDA restrictions FDA statement June 2011 Based on the SEARCH 7 year trial in patients who were considered stable after have had a heart attack.
More informationNEWSLETTER DUE CARE PROGRAM. WINTER 2014 Summer 2015 COMMONLY ASKED QUESTION:
DUE CARE PROGRAM NEWSLETTER WINTER 2014 Summer 2015 Lisa Sather, RPh DUR Coordinator Mountain-Pacific Quality Health 3404 Cooney Drive Helena, MT 59602 406-457-5818 The DUE CARE PROGRAM, administered by
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 2.9: Antiplatelet Drugs Aspirin 75mg Dispersible Tablets Aspirin 300mg Dispersible Tablets Aspirin 300mg Suppositories Clopidogrel 75mg Tablets Dipyridamole
More informationRepatha. Repatha (evolocumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.16.08 Subject: Repatha Page: 1 of 8 Last Review Date: September 18, 2015 Repatha Description Repatha
More informationDrug Interactions: Let me count the ways
: Let me count the ways President: PRN Associates, Ltd. Continuing Education in Pharmacology Tucson, AZ Objectives At the conclusion of this continuing education lesson, the participant will be able to:
More informationHERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised
Name: generic (trade) Dabigatran etexilate (Pradaxa ) HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) DABIGATRAN RECOMMENDED What it is Indications Date decision last revised Direct thrombin inhibitor
More informationa. A pharmacist may order a baseline SCr per protocol
UNITYPOINT HEALTH - MARSHALLTOWN Marshalltown, Iowa PHARMACY POLICY AND PROCEDURE Subject: Anticoagulant Therapy Per Practice Protocol (Formerly Anticoagulant therapy #NPSG.03.05.01) Inpatient Warfarin
More information